(Q43681352)

25 November 2017

title

Combined single-clade candidate HIV-1 vaccines induce T cell responses limited by multiple forms of in vivo immune interference (English)

1 reference

25 November 2017

Anna-Lise Williamson

5

0 references

Carolyn Williamson

4

object named as

Carolyn Williamson

1 reference

25 November 2017

Andrew James McMichael

6

object named as

Andrew J McMichael

1 reference

25 November 2017

Natasha Larke

1

1 reference

25 November 2017

Eung-Jun Im

2

1 reference

25 November 2017

Ralf Wagner

3

1 reference

25 November 2017

Tomás Hanke

7

1 reference

25 November 2017

language of work or name

English

0 references

publication date

1 February 2007

1 reference

European Journal of Immunology

25 November 2017

published in

1 reference

25 November 2017

volume

37

1 reference

25 November 2017

issue

2

1 reference

25 November 2017

page(s)

566-577

1 reference

The role of T cell antagonism and original antigenic sin in genetic immunization

25 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200636711

In vivo modulation of T cell responses and protective immunity by TCR antagonism during infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200636711

Progression of armed CTL from draining lymph node to spleen shortly after localized infection with herpes simplex virus 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200636711

Evolutionary and immunological implications of contemporary HIV-1 variation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200636711

7 January 2021

Studies on the cross-clade and cross-species conservation of HIV-1 Gag-specific CD8 and CD4 T cell responses elicited by a clade B DNA/MVA vaccine in macaques

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200636711

7 January 2021

Cross-reactive memory T cells for Epstein-Barr virus augment the alloresponse to common human leukocyte antigens: degenerate recognition of major histocompatibility complex-bound peptide by T cells and its role in alloreactivity

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200636711

7 January 2021

Cross-clade-specific cytotoxic T lymphocytes in HIV-1-infected children

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200636711

7 January 2021

Clade B-based HIV-1 vaccines elicit cross-clade cytotoxic T lymphocyte reactivities in uninfected volunteers

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200636711

7 January 2021

The repertoire of T cells shaped by a single MHC/peptide ligand.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200636711

7 January 2021

A functional and structural basis for TCR cross-reactivity in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200636711

7 January 2021

T cell receptor repertoire for a viral epitope in humans is diversified by tolerance to a background major histocompatibility complex antigen

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200636711

7 January 2021

Distinct recognition of non-clade B human immunodeficiency virus type 1 epitopes by cytotoxic T lymphocytes generated from donors infected in Africa

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200636711

7 January 2021

Recognition of influenza A matrix protein by HLA-A2-restricted cytotoxic T lymphocytes. Use of analogues to orientate the matrix peptide in the HLA-A2 binding site

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200636711

7 January 2021

T cell cross-reactivity and conformational changes during TCR engagement

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200636711

7 January 2021

HIV T cell vaccines, the importance of clades

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200636711

7 January 2021

Disquisitions of Original Antigenic Sin. I. Evidence in man

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200636711

7 January 2021

Disquisitions on Original Antigenic Sin. II. Proof in lower creatures

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200636711

7 January 2021

Original antigenic sin impairs cytotoxic T lymphocyte responses to viruses bearing variant epitopes

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200636711

7 January 2021

Original antigenic sin and apoptosis in the pathogenesis of dengue hemorrhagic fever

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200636711

7 January 2021

Natural variants of cytotoxic epitopes are T-cell receptor antagonists for antiviral cytotoxic T cells

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200636711

7 January 2021

Cytotoxic T-cell activity antagonized by naturally occurring HIV-1 Gag variants

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200636711

7 January 2021

In vivo antagonism of a T cell response by an endogenously expressed ligand

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200636711

7 January 2021

Association of malaria parasite population structure, HLA, and immunological antagonism.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200636711

7 January 2021

Altered peptide ligands narrow the repertoire of cellular immune responses by interfering with T-cell priming

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200636711

7 January 2021

Immunodominance in major histocompatibility complex class I-restricted T lymphocyte responses

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200636711

7 January 2021

Determinants of human immunodeficiency virus type 1 escape from the primary CD8+ cytotoxic T lymphocyte response

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200636711

7 January 2021

Characterization of a polyclonal cytolytic T lymphocyte response to human immunodeficiency virus in persons without clinical progression

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200636711

7 January 2021

Immune-mediated positive selection drives human immunodeficiency virus type 1 molecular variation and predicts disease duration.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200636711

7 January 2021

HLA class I homozygosity accelerates disease progression in human immunodeficiency virus type 1 infection.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200636711

7 January 2021

Design and construction of an experimental HIV-1 vaccine for a year-2000 clinical trial in Kenya

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200636711

7 January 2021

Engineering RENTA, a DNA prime-MVA boost HIV vaccine tailored for Eastern and Central Africa

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200636711

7 January 2021

Therapeutic immunization of highly active antiretroviral therapy-treated HIV-1-infected patients: safety and immunogenicity of an HIV-1 gag/poly-epitope DNA vaccine

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200636711

7 January 2021

Expansion and diversification of virus-specific T cells following immunization of human immunodeficiency virus type 1 (HIV-1)-infected individuals with a recombinant modified vaccinia virus Ankara/HIV-1 Gag vaccine.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200636711

7 January 2021

Induction of multifunctional human immunodeficiency virus type 1 (HIV-1)-specific T cells capable of proliferation in healthy subjects by using a prime-boost regimen of DNA- and modified vaccinia virus Ankara-vectored vaccines expressing HIV-1 Gag c

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200636711

7 January 2021

A human immunodeficiency virus 1 (HIV-1) clade A vaccine in clinical trials: stimulation of HIV-specific T-cell responses by DNA and recombinant modified vaccinia virus Ankara (MVA) vaccines in humans

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200636711

7 January 2021

An immunodominant epitope of the human immunodeficiency virus envelope glycoprotein gp160 recognized by class I major histocompatibility complex molecule-restricted murine cytotoxic T lymphocytes.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200636711

7 January 2021

Attenuated poxviruses expressing a synthetic HIV protein stimulate HLA-A2-restricted cytotoxic T-cell responses

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200636711

7 January 2021

Design and preclinical evaluation of a multigene human immunodeficiency virus type 1 subtype C DNA vaccine for clinical trial

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200636711

7 January 2021

Immunogenicity of Multiple Gene and Clade Human Immunodeficiency Virus Type 1 DNA Vaccines

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200636711

7 January 2021

Multiclade human immunodeficiency virus type 1 envelope immunogens elicit broad cellular and humoral immunity in rhesus monkeys

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200636711

7 January 2021

Overcoming original (antigenic) sin.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200636711

7 January 2021

Interactions of single and combined human immunodeficiency virus type 1 (HIV-1) DNA vaccines

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200636711

7 January 2021

Reduced immunogenicity of DNA vaccine plasmids in mixtures

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200636711

7 January 2021

Vaccine route, dose and type of delivery vector determine patterns of primary CD8+ T cell responses.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200636711

7 January 2021

In vivo compartmentalization of functionally distinct, rapidly responsive antigen-specific T-cell populations in DNA-immunized or Salmonella enterica serovar Typhimurium-infected mice

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200636711

7 January 2021

CD8+ T cells responding to influenza infection reach and persist at higher numbers than CD4+ T cells independently of precursor frequency

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200636711

7 January 2021

Centralized immunogens as a vaccine strategy to overcome HIV-1 diversity

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200636711

7 January 2021

Identifiers

DOI

10.1002/EJI.200636711

1 reference

25 November 2017

1 reference